LL-37vsVIP

LL-37 is the only cathelicidin-derived antimicrobial peptide in humans, cleaved from the precursor protein hCAP-18 by proteinase 3 in neutrophil granules. It functions as a critical component of the innate immune system's first line of defense, with both direct antimicrobial activity and sophisticated immunomodulatory signaling.

The direct antimicrobial mechanism relies on LL-37's amphipathic alpha-helical structure — one face is positively charged (cationic) while the other is hydrophobic. The cationic face electrostatically attracts the negatively charged phospholipid headgroups of bacterial membranes (which differ from mammalian membranes in their lipid composition and charge distribution). Once bound, the hydrophobic face inserts into the lipid bilayer, creating pores or disrupting membrane integrity through a 'carpet' or 'toroidal pore' mechanism. This physical membrane disruption kills bacteria, fungi, and enveloped viruses rapidly and is difficult for microbes to develop resistance against, unlike conventional antibiotics that target specific enzymes.

The immunomodulatory functions are equally important. LL-37 acts as a chemoattractant for neutrophils, monocytes, and T cells through formyl peptide receptor-like 1 (FPRL1) activation, recruiting immune cells to infection sites. It promotes macrophage phagocytosis and enhances the killing capacity of neutrophil extracellular traps (NETs). Critically, LL-37 neutralizes bacterial lipopolysaccharide (LPS/endotoxin), preventing the cytokine storm that leads to sepsis. It also stimulates angiogenesis through VEGF upregulation and promotes wound re-epithelialization by activating epidermal growth factor receptor (EGFR) transactivation. LL-37 production is upregulated by vitamin D (which is why vitamin D status affects innate immunity), and its expression is found in skin, airways, the gastrointestinal tract, and virtually all epithelial barrier tissues.

Vasoactive Intestinal Peptide is a 28-amino-acid neuropeptide that belongs to the secretin/glucagon superfamily. It is widely distributed throughout the body — found in neurons of the central and peripheral nervous systems, immune cells, and the gastrointestinal tract — and acts through two G protein-coupled receptors: VPAC1 (expressed broadly) and VPAC2 (more restricted to CNS and immune tissue). Both receptors couple to Gs proteins, activating adenylyl cyclase and raising intracellular cAMP.

VIP's vasodilatory effect is among the most potent in the body. It relaxes vascular, airway, and gastrointestinal smooth muscle by activating cAMP/PKA signaling, which phosphorylates myosin light chain kinase and reduces calcium sensitivity in smooth muscle cells. In the pulmonary vasculature, this produces bronchodilation and reduced pulmonary artery pressure. In cerebral vasculature, VIP is a key regulator of blood flow.

The immunomodulatory effects are particularly relevant for its use in chronic inflammatory response syndrome (CIRS). VIP powerfully suppresses the Th1 (pro-inflammatory) immune response while promoting Th2 and regulatory T cell (Treg) differentiation. It inhibits macrophage production of TNF-α, IL-6, IL-12, and nitric oxide, and suppresses dendritic cell maturation and antigen presentation. This immune-balancing effect makes VIP valuable in conditions characterized by chronic Th1/Th17 immune dysregulation, such as mold illness/CIRS. In the brain, VIP is neuroprotective — it upregulates BDNF and activity-dependent neuroprotective protein (ADNP), supports circadian rhythm regulation in the suprachiasmatic nucleus, and protects neurons from inflammatory and oxidative damage. The extremely short plasma half-life (1-2 minutes) necessitates intranasal delivery for CNS effects, bypassing the blood-brain barrier through olfactory and trigeminal nerve transport.